How AHR and NLRP6 affect the gut lining in colitis
AHR-NLRP6 interactions in gut barrier dysfunction and colitis
['FUNDING_R01'] · UNIVERSITY OF LOUISVILLE · NIH-11401873
This work explores whether a gut microbe–derived compound called Urolithin A can strengthen the intestinal barrier and help people with inflammatory bowel disease like Crohn’s and ulcerative colitis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF LOUISVILLE (nih funded) |
| Locations | 1 site (LOUISVILLE, UNITED STATES) |
| Trial ID | NIH-11401873 on ClinicalTrials.gov |
What this research studies
As someone with IBD, this project focuses on how a natural compound (Urolithin A) interacts with gut cell sensors called AHR and NLRP6 to protect the intestinal lining. Researchers will use lab-grown intestinal cells and animal models of colitis to follow the AHR–NLRP6–IL-18 pathway and the downstream IL-22 signals from immune cells. They will study how these signals promote goblet cell differentiation and mucin production that form the mucus barrier. The aim is to identify steps that could be targeted to restore barrier function and reduce inflammation in people with Crohn’s disease or ulcerative colitis.
Who could benefit from this research
Good fit: People with inflammatory bowel disease (ulcerative colitis or Crohn’s disease), especially those with active gut barrier problems, would be the most relevant candidates for future therapies from this work.
Not a fit: People without inflammatory bowel disease or whose symptoms are caused by unrelated conditions are unlikely to benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that strengthen the intestinal lining and reduce flares in people with Crohn’s disease and ulcerative colitis.
How similar studies have performed: Prior laboratory and animal studies showed that Urolithin A can improve gut barrier function and lessen colitis, but human clinical testing of this approach remains limited.
Where this research is happening
LOUISVILLE, UNITED STATES
- UNIVERSITY OF LOUISVILLE — LOUISVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JALA, VENKATAKRISHNA RAO — UNIVERSITY OF LOUISVILLE
- Study coordinator: JALA, VENKATAKRISHNA RAO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.